Association for Molecular Pathology v. Myriad Genetics, Inc.
Holding
A naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but synthetic complementary DNA ("cDNA") is patent eligible because it is not naturally occurring.
Judgment
Affirmed in part and reversed in part., 9-0, in an opinion by Clarence Thomas on Jun 13, 2013. Justice Scalia filed an opinion concurring in part and concurring in the judgment.
Holding: A naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but synthetic complementary DNA (“cDNA”) is patent eligible because it is not naturally occurring.
Judgment:”Affirmed in part and reversed in part., 9-0, in an opinion by Justice Thomas on June 13, 2013. Justice Scalia filed an opinion concurring in part and concurring in the judgment.
Recommended Citation: Association for Molecular Pathology v. Myriad Genetics, Inc., SCOTUSblog, https://www.scotusblog.com/cases/association-for-molecular-pathology-v-myriad-genetics-inc/